Relative Progression-Free Survival Over Time with Novel Triplet Regimens for the Treatment of Relapsed/Refractory Multiple Myeloma

In combination with lenalidomide (Revlimid ®, R) and dexamethasone (d), elotuzumab (Empliciti™, E), carfilzomib (Kyprolis®, K), ixazomib (Ninlaro®, N) and daratumumab (Darzalex®, D) have been approved for treatment of relapsed/refractory multiple myeloma (RRMM). In randomized, controlled trials, ERd, KRd, NRd and DRd reduced the risk o f disease progression/death versus Rd. However, there are no known head-to-head trials comparing these regimens.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research